Carl Grunfeld, MD, PhD

Headshot of Carl Grunfeld
User Profile Photo

Carl Grunfeld, MD, PhD

User Profile Name
Member, CFAR Scientific Council
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Our laboratory studies the metabolic disturbances that occur during infection. Our major focuses are changes in lipid metabolism and energy balance. Using intact animals, we determine the physiological consequences of the host response to infection and define the cytokine mediators. We then determine the underlying cellular and molecular basis for these changes using both in vivo animal studies and cultured cells. For example, we have identified regulation in the activity of lipid synthesizing enzymes and related proteins that occurs at the level of transcription or post translation. For transcriptional regulation, the response elements and transactivating factors are then defined. Transgenic mouse models are developed to define the roles of key molecules in the host response.

Our laboratory has shown that many of the metabolic changes are part of host defense and not detrimental. We have shown that lipoproteins induced during the host response to infection scavenge toxic bacterial fragments such as LPS and LTA. We have defined the molecules involved in their neutralization.

With regard to energy balance, we determined the mechanisms that induce wasting in AIDS. We also developed specific therapies. We have recently identified a candidate for the molecule that generates fever during the response to infection: Uncoupling Protein 2 (UCP2).

Primary Thematic Area:
Vascular & Cardiac Biology
Secondary Thematic Area:
Immunology
Research Summary:
Metabolic Changes and the Host Response to Infection
User Profile Bio

Displaying 101 - 125 of 305

  1. Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, Wen MJ, Lee GA, Grunfeld C, Schambelan M. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab. 2009 Apr; 94(4):1137-44.
  2. Gibert CL, Shlay JC, Sharma S, Bartsch G, Peng G, Grunfeld C, Terry Beirn Community Programs for Clinical Research on AIDS , International Network for Strategic Initiatives in Global HIV Trials . Racial differences in changes of metabolic parameters and body composition in antiretroviral therapy-naive persons initiating antiretroviral therapy. . 2009 Jan 01; 50(1):44-53.
  3. Grunfeld C, Feingold KR. Endotoxin in the gut and chylomicrons: translocation or transportation? J Lipid Res. 2009 Jan; 50(1):1-2.
  4. Lu B, Lu Y, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. LPS and proinflammatory cytokines decrease lipin-1 in mouse adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2008 Dec; 295(6):E1502-9.
  5. Scherzer R, Shen W, Bacchetti P, Kotler D, Lewis CE, Shlipak MG, Punyanitya M, Heymsfield SB, Grunfeld C, Study of Fat Redistribution Metabolic Change in HIV Infection . Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. Am J Clin Nutr. 2008 Oct; 88(4):1088-96.
  6. Grunfeld C. Understanding the complications of antiretroviral drugs. Clin Infect Dis. 2008 Aug 15; 47(4):575-6.
  7. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun. 2008 Sep 19; 374(2):341-4.
  8. Feingold KR, Wang Y, Moser A, Shigenaga JK, Grunfeld C. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J Lipid Res. 2008 Oct; 49(10):2179-87.
  9. Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, Masur H, Meigs JB, Mulligan K, Reiss P, Samaras K, Working Group 1 . Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation. 2008 Jul 08; 118(2):e20-8.
  10. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dubé MP, Lipshultz SE, Hsue PY, Squires K, Schambelan M, Wilson PW, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008 Jul 08; 118(2):198-210.
  11. Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, Shane E, Golub ET, Anastos K. Short-term bone loss in HIV-infected premenopausal women. . 2010 Feb; 53(2):202-8.
  12. Grunfeld C. Insulin resistance in HIV infection: drugs, host responses, or restoration to health? Top HIV Med. 2008 Jun-Jul; 16(2):89-93.
  13. Scherzer R, Shen W, Bacchetti P, Kotler D, Lewis CE, Shlipak MG, Heymsfield SB, Grunfeld C, Study of Fat Redistribution Metabolic Change in HIV Infection (FRAM) . Simple anthropometric measures correlate with metabolic risk indicators as strongly as magnetic resonance imaging-measured adipose tissue depots in both HIV-infected and control subjects. Am J Clin Nutr. 2008 Jun; 87(6):1809-17.
  14. Grunfeld C, Feingold KR. HDL and innate immunity: a tale of two apolipoproteins. J Lipid Res. 2008 Aug; 49(8):1605-6.
  15. Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. . 2008 May 01; 48(1):53-62.
  16. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, Grunfeld C, FRAM Study Investigators . The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. . 2008 May 01; 48(1):44-52.
  17. Madden E, Lee G, Kotler DP, Wanke C, Lewis CE, Tracy R, Heymsfield S, Shlipak MG, Bacchetti P, Scherzer R, Grunfeld C. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS. 2008 Mar 30; 22(6):707-15.
  18. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep. 2008 Feb; 10(1):61-70.
  19. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, Tien PC, Shlipak MG, Sidney S, Polak JF, O'Leary D, Bacchetti P, Kronmal RA. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009 Sep 10; 23(14):1841-9.
  20. Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis. 2008 Jul; 199(1):19-26.
  21. Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, Shlipak MG. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med. 2007 Nov 12; 167(20):2213-9.
  22. Grunfeld C, Rimland D, Gibert CL, Powderly WG, Sidney S, Shlipak MG, Bacchetti P, Scherzer R, Haffner S, Heymsfield SB. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. . 2007 Nov 01; 46(3):283-90.
  23. Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007 Oct 18; 21(16):2183-90.
  24. Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, Scherzer R, Grunfeld C. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab. 2008 Jan; 93(1):216-24.
  25. Lee D, Benson CA, Lewis CE, Grunfeld C, Scherzer R. Prevalence and factors associated with dry skin in HIV infection: the FRAM study. AIDS. 2007 Oct 01; 21(15):2051-7.